Literature DB >> 6253079

DNA of Epstein-Barr virus VIII: B95-8, the previous prototype, is an unusual deletion derivative.

N Raab-Traub, T Dambaugh, E Kieff.   

Abstract

B95-8, an infectious mononucleosis-derived isolate of Epstein-Barr virus (EBV), is biologically and antigenically indistinguishable from other isolates of EBV and has been the prototype for previous studies of EBV DNA. The long unique region UL of the DNA of a Burkitt tumor isolate, W91, is 9 X 10(6) daltons longer than the UL of B95-8. The "additional DNA and the regions around it have been cloned from W91 and another Burkitt tumor isolate, AG876. The additional DNA is viral and not cellular, since W91 and AG876 have almost identical additional DNA, and there is no detectable homology to human lymphocyte DNA. The insertion site of the additional DNA is within the 0.96 X 10(6) dalton Hinf 1 fragment of B95-8 Bam Hl l. After infection and transformation of five cell lines B95-8 did not pick up additional DNA in this region. Hybridization of labeled DNAs from three EBV-infected cell lines derived from patients with infectious mononucleosis to blots of fragments of the additional DNA indicates that these sequences are present in American as well as in African virus. B95-8 is therefore an unusual deletion derivative. A newly discovered feature of EBV DNAs is that sequences which map near the left end of UL have homology to part of the additional DNA.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6253079     DOI: 10.1016/0092-8674(80)90173-7

Source DB:  PubMed          Journal:  Cell        ISSN: 0092-8674            Impact factor:   41.582


  102 in total

1.  Epstein-Barr virus nuclear protein 2 is a key determinant of lymphocyte transformation.

Authors:  J I Cohen; F Wang; J Mannick; E Kieff
Journal:  Proc Natl Acad Sci U S A       Date:  1989-12       Impact factor: 11.205

2.  Coinfection with multiple strains of the Epstein-Barr virus in human immunodeficiency virus-associated hairy leukoplakia.

Authors:  D M Walling; S N Edmiston; J W Sixbey; M Abdel-Hamid; L Resnick; N Raab-Traub
Journal:  Proc Natl Acad Sci U S A       Date:  1992-07-15       Impact factor: 11.205

3.  Epstein-Barr virus LF2 protein regulates viral replication by altering Rta subcellular localization.

Authors:  Andreas M F Heilmann; Michael A Calderwood; Eric Johannsen
Journal:  J Virol       Date:  2010-07-14       Impact factor: 5.103

4.  Infection of Epstein-Barr virus in a gastric carcinoma cell line induces anchorage independence and global changes in gene expression.

Authors:  Aron R Marquitz; Anuja Mathur; Kathy H Y Shair; Nancy Raab-Traub
Journal:  Proc Natl Acad Sci U S A       Date:  2012-05-30       Impact factor: 11.205

Review 5.  EBV Persistence--Introducing the Virus.

Authors:  David A Thorley-Lawson
Journal:  Curr Top Microbiol Immunol       Date:  2015       Impact factor: 4.291

6.  Host Gene Expression Is Regulated by Two Types of Noncoding RNAs Transcribed from the Epstein-Barr Virus BamHI A Rightward Transcript Region.

Authors:  Aron R Marquitz; Anuja Mathur; Rachel Hood Edwards; Nancy Raab-Traub
Journal:  J Virol       Date:  2015-08-26       Impact factor: 5.103

7.  B-cell lymphoproliferation and lymphomagenesis are associated with clonotypic intracellular terminal regions of the Epstein-Barr virus.

Authors:  N A Brown; C R Liu; Y F Wang; C R Garcia
Journal:  J Virol       Date:  1988-03       Impact factor: 5.103

8.  Identification and characterization of an Epstein-Barr virus early antigen that is encoded by the NotI repeats.

Authors:  C M Nuebling; N Mueller-Lantzsch
Journal:  J Virol       Date:  1989-11       Impact factor: 5.103

9.  A Genome-Wide Epstein-Barr Virus Polyadenylation Map and Its Antisense RNA to EBNA.

Authors:  Vladimir Majerciak; Wenjing Yang; Jing Zheng; Jun Zhu; Zhi-Ming Zheng
Journal:  J Virol       Date:  2019-01-04       Impact factor: 5.103

10.  Structure of defective DNA molecules in Epstein-Barr virus preparations from P3HR-1 cells.

Authors:  M S Cho; G W Bornkamm; H zur Hausen
Journal:  J Virol       Date:  1984-07       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.